Home › Calculator › BCRX Dividend Calculator 2026
BCRX Dividend DRIP Calculator 2026
18.66% YieldHealthcareBioCryst Pharmaceuticals, Inc. · NASDAQ
Price: $10.72 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BCRX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BCRX snowball 📈
$10,000 in BCRX → $12.27M in 10 years · $186.26/month
About BioCryst Pharmaceuticals, Inc. (BCRX) — Dividend Analysis 2026
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Compare BCRX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BCRX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BCRX position with:
🌍 BCRX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BCRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 18.66% | 15.86% | $1,866 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 15.86% | 13.06% | $1,586 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 14.93% | 12.13% | $1,493 / yr |
| 🇬🇧 UK ISA | 0% | 18.66% | 15.86% | $1,866 / yr |
| 🇬🇧 UK Taxable | 8.75% | 17.03% | 14.23% | $1,703 / yr |
| 🇨🇦 TFSA | 0% | 18.66% | 15.86% | $1,866 / yr |
| 🇨🇦 CA Taxable | 25% | 14.00% | 11.20% | $1,400 / yr |
| 🇦🇺 Super (pension) | 15% | 15.86% | 13.06% | $1,586 / yr |
| 🇦🇺 AU Taxable | 30% | 13.06% | 10.26% | $1,306 / yr |
| 🇩🇪 DE Taxable | 26.375% | 13.74% | 10.94% | $1,374 / yr |
| 🇫🇷 FR Taxable | 30% | 13.06% | 10.26% | $1,306 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BCRX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BCRX Dividend Payment Schedule
BCRX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BCRX vs Healthcare Benchmarks
How BCRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BCRX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BCRX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-11 | 33,540 | $8.50 | $285.1K | ||
| A-Award | 2026-06-11 | 15,294 | — | — | ||
| A-Award | 2026-06-11 | 33,540 | $8.50 | $285.1K | ||
| A-Award | 2026-06-11 | 15,294 | — | — | ||
| A-Award | 2026-06-11 | 15,294 | — | — | ||
| A-Award | 2026-06-11 | 33,540 | $8.50 | $285.1K | ||
| A-Award | 2026-06-11 | 15,294 | — | — | ||
| A-Award | 2026-06-11 | 33,540 | $8.50 | $285.1K | ||
| A-Award | 2026-06-11 | 15,294 | — | — | ||
| A-Award | 2026-06-11 | 33,540 | $8.50 | $285.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BCRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
BioCryst Pharmaceuticals, Inc. (BCRX) is currently trading at $10.72, 36% below its 52-week high. The current dividend yield is 18.66% based on an annual payout of $2.00 per share.
BCRX (BioCryst Pharmaceuticals, Inc.) — 18.66% Dividend Yield Analysis
BioCryst Pharmaceuticals, Inc. (BCRX) is a healthcare stock currently trading at $10.72 with a dividend yield of 18.66%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (18.66%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.